icon-folder.gif   Conference Reports for NATAP  
  Feb 2009 Hong Kong
19th APASL-
Conference of the Asian Pacific Association for the Study of the Liver 2009
Back grey_arrow_rt.gif
Histologic Assessment of Long-term Entecavir
(ETV) Treatment in Chronic Hepatitis B (CHB) Patients

  Reported by Jules Levin
Feb 2009 Hong Kong
19th APASL- Conference of the Asian Pacific Association for the Study of the Liver 2009
F. Imazeki1, M. Kage2, M. Moriyama3, H. Kumada4, H. Kobashi5, J. Toyota6, K. Takaguchi7, N. Izumi8, H. Ikeda9, S. Fujioka10, Y. Katano11, M. Sata12, H. Ishikawa13, T. Seriu13, O. Yokosuka1, M. Omata14 1Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan; 2Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan; 3Division of Gastroenterology and Hepatology, Department of medicine, Nihon University School of Medicine, Tokyo, Japan; 4Department of Gastroenterology and Hepatology, Toranomon Hospital, Tokyo, Japan; 5Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; 6Department of Hepatology, Sapporo Kosei General Hospital, Hokkaido, Japan; 7Department of Internal Medicine, Kagawa Prefectural Central Hospital, Kagawa, Japan; 8Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan; 9Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Okayama, Japan; 10Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan; 11Department of Gastroenterology, Graduate School of Medicine, Nagoya University, Aichi, Japan; 12Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan; 13Research and Development, Bristol-Myers Squibb K.K., Tokyo, Japan; 14Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Author Summary of Results
Three years of ETV treatment resulted in histologic improvement in 100% of nucleoside-na´ve and 89% of LVDr patients
Treatment with ETV beyond 48 weeks resulted in further improvement in fibrosis scores in both na´ve and LVDr patients
High proportions of both na´ve and LVDr patients achieved HBV DNA suppression and ALT normalization during 3 years of ETV
Mean albumin and platelet counts continued to increase between week 48 and week 148 (data not shown).
Author Conclusion
The results from these cohorts demonstrate that long-term continuous treatment with ETV results in durable suppression of HBV replication and significant histologic improvement in nucleoside-na´ve and LVDr patients
In large observational studies, elevated baseline HBV DNA has been demonstrated to be a significant risk factor for cirrhosis and hepatocellular carcinoma1-3
HBV DNA suppression with antiviral therapy can significantly improve liver histology in HBeAg(+) patients4
Entecavir (ETV) demonstrated potent suppression of HBV DNA replication and improvement in liver histology in nucleoside-na´ve and lamivudine-refractory (LVDr) Japanese patients with chronic hepatitis B (CHB) (studies ETV-053 and ETV-052)5,6
All patients who completed studies ETV-053 and ETV-052 could enroll in rollover study ETV-060
We present histologic results from nucleoside-na´ve and LVDr patients who received at least 3 years of ETV therapy in studies ETV-052, ETV-053 and ETV-060










1. Chen CJ, Yang HI, Su J, et al. JAMA 2006;295:65-73.
2. Iloeje UH, Yang HI, Su J, et al. Gastroenterology 2006;130:678-686.
3. Chen G, Lin W, Shen F, et al. Am J Gastroenterol 2006;101:1797-1803.
4. Mommeja-Marin H, Mondou E, Blum MR, et al. Hepatology 2003;37:1309-1319.
5. Kobashi H, Takaguchi K, Ikeda H, et al. J Gastroenterol Hepatol 2009. In press.
6. Suzuki F, Toyoda J, Katano Y, et al. J Gastroenterol Hepatol 2008;23:1320-26.